Merck’s sacituzumab tirumotecan cuts death risk by 32% in Phase 3 endometrial cancer trial
+3 new sources since this summary was written
Merck and partner Kelun‑Biotech reported results of the global Phase 3 TroFuse‑005 trial of sacituzumab tirumotecan (sac‑TMT) in patients with advanced or recurrent endometrial cancer who had prior platinum‑based chemotherapy and anti‑PD‑1/L1 therapy. The study showed a 32% reduction in overall‑death risk and a 41% reduction in disease‑progression‑or‑death risk versus physician’s‑choice chemotherapy, extending median overall survival by 6.9 months. The U.S. FDA has accepted a biologics license application for priority review with a PDUFA target date of June 15 2027.
Why it matters
The survival benefit and risk‑reduction data give Merck a clear regulatory pathway; if approved, sac‑TMT would become a new standard of care for this heavily pre‑treated patient group, potentially driving revenue growth for Merck. The FDA’s priority‑review status also signals a faster timeline for market entry, which could affect investors’ valuation of MRK.
Key facts
- 1The TroFuse‑005 trial enrolled 776 patients at more than 200 centers in 29 countries. prnewswire.com
- 2Sac‑TMT reduced the risk of death by 32% (hazard ratio = 0.68; 95% CI 0.55‑0.84). merck.com
- 3Sac‑TMT reduced the risk of disease progression or death by 41% (hazard ratio = 0.59; 95% CI 0.50‑0.70). merck.com
- 4Median overall survival was 19.0 months with sac‑TMT versus 12.1 months with chemotherapy, a 6.9‑month extension. merck.com
- 5The U.S. FDA accepted a biologics license application for sac‑TMT for priority review with a PDUFA target date of June 15 2027. merck.com
- 6Treatment‑related adverse events of any grade occurred in 97.1% of sac‑TMT patients and 89.6% of chemotherapy patients. merck.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.